Title: CANCIDAS caspofungin acetate for intravenous injection
1CANCIDAS? (caspofungin acetate)for intravenous
injection
- NDA 21-227
- Merck Co., Inc.
2Safety and Efficacy of CANCIDAS? (caspofungin
acetate) in Invasive Aspergillosis
- Eileen Navarro, M.D., Medical Officer
- Division of Special Pathogen and Immunologic Drug
Products - CDER/FDA
3FDA Review Team for NDA 21-227
- Regulatory Project Manager L. Chan, R.Ph.
- Chemistry G. Holbert, Ph.D. D.
Matecka, Ph.D. - Microbiology S. Bala, Ph.D.
- Pharmacokinetics/Biopharmaceutics H. Mahayni,
Ph.D. - Pharmacotoxicologist O. McMaster, Ph.D.
- Biostatistician C. Dixon, Ph.D.
- Clinical E. Navarro, M.D. L. Sacks,
M.D. - OPDRA consultant J. Staffa, Ph.D.
-
4Outline
- 1. CANCIDAS? proposed labeling, microbiology,
pharmacokinetics - 2. Efficacy of CANCIDAS? as therapy for
refractory or intolerant invasive aspergillosis - 3. Safety of CANCIDAS? in healthy subjects and in
patients with fungal infections
5Proposed Labeling
- Indication
- CANCIDAS? is indicated for the treatment of
invasive aspergillosis in patients who are
refractory to or intolerant of other therapies. - Dosage
- A single 70-mg loading dose ... administered on
Day 1, followed by 50 mg daily.
6Proposed Dosage Adjustments
- Increase
- ...available safety data suggests an increase to
70 mg daily ...in patients without evidence of
clinical response - Decrease
- In patients with moderate hepatic insufficiency
CANCIDAS 35 mg daily is recommended - No dosage adjustment is necessary for patients
with renal insufficiency.
7Microbiology
- Gene inhibition ? cell membrane enzyme modulation
? cell wall glucan reduction - Time kinetics studies slower kill rate for C.
albicans - (7 hours caspofungin vs 1 hour Amphotericin B
) - Activity specific for actively growing hyphae
- Activity for Aspergillus spp not fungicidal
- ? activity against Fusarium, Trichosporon, Mucor
spp
8Comparative Efficacy of Caspofungin and
Amphotericin B in Granulocytic Rabbits with
Invasive Pulmonary Aspergillosis
9Pharmacokinetics
- Concentrations are more variable in patients
- Trough levels gt1 ?g/ml are immediately achieved
with a 70 mg loading dose - CNS distribution low in rodents unknown in humans
10Pharmacokinetics
- No adjustment for itraconazole, amphotericin B,
and mycophenolate mofetil - Reduces tacrolimus levels
- Cyclosporine increases caspofungin AUC by 35
- NOT an inhibitor or a substrate of CYP isoenzymes
- Potential metabolic inducers nelfinavir, CYP
3A4 inducers (rifampin, phenobarbital)
11Outline
- 1. CANCIDAS? proposed labeling, microbiology,
pharmacokinetics - 2. Efficacy of CANCIDAS? as therapy for
refractory or intolerant invasive aspergillosis - 3. Safety of CANCIDAS? in healthy subjects and in
patients with fungal infections
12Clinical StudiesInvasive Aspergillosis
- Clinical trials
- Study 019 Open label N 69
- Study 024 Compassionate use N 3
- Historical control
- Study 028/029 N 229
13Clinical StudiesMucosal Candidiasis
14Protocol Summary Highlights for Studies 019 and
028/029
- Procedures
- Disease definition
- Response to prior therapy
- Timing of assessments
- Outcome definitions
- Study design and analysis
15Study 019 Study Procedures
16Study 028 Study Procedures
- Case finding pathology/microbiology department,
subspecialty consultation and hospital
discharge registries - Sites 4/10 participated in Study 019
- Data chart abstraction
- Outcome assessment site investigator
17Exclusion Criteria
18Study 019 and Study 028/029Exclusion Criteria
- Severity of underlying disease
- a) Abnormal Lab values
- Hemoglobin lt8 gm/dL
- Platelet count lt25,000/?L
- INR gt 1.6
- Bilirubin gt3 times the upper limit of normal
- AST or ALT gt 5 times the upper limit of normal
- b) Patients who were not expected to survive
- at least 5 days (after 7 days of prior
therapy)
19Disease Definition
- DEFINITE
- Pulmonary histopathology OR tissue cultures
- Extrapulmonary histopathology (invasion of
affected tissue)
20Disease Definition
21Response to Prior Therapy
- Refractory
- progression or failure to improve despite AmB,
lipid formulation AmB, itraconazole, or
investigational azole - Intolerance
- renal
- baseline doubling or creatinine gt2.5 mg/dL
- other infusion toxicities
- Study 028 intolerance (creatinine gt2.5 mg/dL)
22Study 019 and 028/029Timing of Assessments
- Response to prior therapy
- Refractory ?7 days
- Intolerance undefined
- Study 019
- Response to caspofungin therapy EOT
- Relapse 4 weeks post EOT
23Study 019 and 028/029Outcome Definitions
- Favorable
- Complete response resolution of IA
- Partial response improvement
- clinical, x-ray, bronchoscopic findings
- Unfavorable
- Stable non-progressive disease
- Failure progression or death
24Expert Panel Assessment
25Expert Panel Assessment
26Study 019 Study Design
- Efficacy estimation study
- response rate 30
- Population Primary MITT 1 dose
- Secondary CE gt 7days
- Expert Panel superceded MITT
-
- Safety 95 probability of detecting at least
1 - DRAE if the incidence is ? 5.8
27Study 019 and 028/029Data Analysis
- Primary proportion of success at EOT
-
- Secondary logistic regression analysis
- Adjusted for predictive/baseline risk
- variables
28Study 019 Patient Accounting(May 1998- April
2000)
- N
- Enrolled 69
- Excluded - 6
- Evaluable 63
- Reason for Exclusion
- protocol violation 1
- another pathogen identified 3
- unevaluable 2
29Study 028 Patient Accounting1995-1998
30Baseline Characteristics
31Baseline Characteristics (cont.)
32Baseline Characteristics (cont.)
33Baseline Characteristics Prior Therapy in Study
019 and 028/029
34Duration of Prior/Standard Therapy
35Total Treatment Duration for Current
Aspergillosis Infection
36Applicant Clinical Efficacy Rates
-
- Study 019 Study 028/029
- Expert Panel Investigator
-
- Population n/N () n/N ()
- All patients 26/63 (41.3) 35/206 (17.0)
- Response to prior therapy
- Refractory 19/53 (35.8) 27/188 (14.4)
- Intolerant Only 7/10 (70.0) 3/5
(60.0) - Site of infection
- Pulmonary 21/45 (46.7) 32/154 (20.8)
- All other sites 5/18 (27.8) 3/52 (5.8)
37Complete Responses and Relapse
38Complete Response to Caspofungin
- Identifier 219 330 366 065
- Extent of IA pulmonary pulmonary skull
pulmonary - Underlying disease allo BMT lymphoma diabetes
leukemia - Prior treatment AmB/ ABLC Itraconazole AmB
ABLC, Itra - lobectomy resection
- Caspofungin Rx (days) 8 28 27 90
- Death yes no no no
- Relapse N/A no no no
- possible brain abscess
- CT nodules without cavitation, (-) BAL cultures
with suggestive direct - examination
-
39Clinical Efficacy Rates by Baseline Risk
40Clinical Efficacy Rates by Geographic Region
41Clinical Efficacy Rates by Total Duration of
Treatment
42Central nervous system involvement in patients
with IA
- Success in CNS involvement 2/6
- CNS aspergillosis emerging on treatment 2
- Day 16 and 58 of therapy
43Post-Caspofungin Therapy
- Patient Initial RX Final treatment Outcome
- 0002 AmB, ABCD AmBisome surgery died
- 0056 AmBisome AmBisome failure
- 0057 ABLC, azole lipid AmB failure
- 0059 Itra, ABLC, AmBisome surgery failure
- lipid AmB
- 0186 ABLC ABLC failure
- 0187 AmB, ABLC, ABLC died
- 0246 Itra, AmB AmBisome died
- 0296 AmB, Itra ABLC failed
- 0412 azole, Itra AmB failed
- 0446 lipid AmB, Itra Itraconazole surgery
improved - 0507 AmB azole not known
44Comparability of the Historical Control (028/029)
and the Cancidas-treated Patients (019)
- Comparison is subject to several potential biases
- Information bias
- Bias from secular trends in diagnosis and/or
treatment - Selection bias
45Information Bias
- Assessment of outcome was not as rigorous with
the control group, due to lower quality of
available information - retrospective review of medical records
- incomplete information on concomitant medications
and underlying disease - Expert assessment varied greatly between the two
studies
46Bias from Secular Trends in Diagnosis and/or
Treatment
- Historical control success rate by year of
enrollment increased from 1995 (12.0) to 1998
(20.6) - Improved ability to manage the underlying disease
from 1995 to 2000 - Transplantation (new immunosuppressants)
- Oncology (earlier diagnoses, improved therapy)
47Selection Bias
- Differences in distribution and success rates of
US and foreign patients between studies - Differences in distribution of duration of
therapy for current infection between studies - Differences in the exclusion criteria between
studies
48Summary of Comparability
- All of these biases could act to predispose the
historical control to have a lower success rate
and the CANCIDASTM-treated group to have a higher
success rate, independent of treatment with
CANCIDASTM - Notable differences between 019 and 028/029 may
provide alternative explanations for at least
part of the treatment effects seen - Therefore, it is not clear that all the observed
treatment effect is due to treatment with
CANCIDASTM, and it is difficult to quantify the
potential effect of these biases
49Outline
- 1. CANCIDAS? proposed labeling, microbiology,
pharmacokinetics - 2. Efficacy of CANCIDAS? as therapy for
refractory or intolerant invasive aspergillosis - 3. Safety of CANCIDAS? in healthy subjects and in
patients with fungal infections
50Safety Database
- Clinical Pharmacology 12 Studies 274
- Clinical Studies 338
- 3 comparative Candida 263
- 1 variable dose Candida 14
- 1 Aspergillus study 58
- 1 compassionate use 3
-
- Total 612
51Drug Exposure
52Overall Caspofungin Safety in Clinical Studies
53Drug-Related Adverse Events
54LFT Elevations Clinical Studies Relative
Elevation gt 3x ULN
- Phase I
- N 257, excluding subjects with impaired
hepatic function - 4 subjects w/ ALT or AST gt3x ULN
- (these 4 patients had normal bilirubin levels)
- Comparative Phase II and Phase III
- Patients w/ ALT or AST gt3x ULN and Bilirubin gt
ULN - Caspofungin vs. Fluconazole
- 6/263 2/93
- (2.3) (2.2)
55Potential Safety Issues
- Elevations in serum calcium / creatinine
- 056 hypercalcemia
- Respiratory adverse events
- 186 pulmonary infiltrates
- 220 pulmonary infiltrates
- Possible histamine reactions
- 1338 rash, pruritus, tachypnea
- 0683 fever, wheeze, rash
56Summary
- 1. CANCIDAS? proposed labeling, microbiology,
pharmacokinetics - 2. Efficacy of CANCIDAS? as therapy for
refractory or intolerant invasive aspergillosis - 3. Safety of CANCIDAS? in healthy subjects and in
patients with fungal infections
57(No Transcript)